RMB Capital Management LLC Sells 25,208 Shares of Tabula Rasa HealthCare, Inc. (NASDAQ:TRHC)

RMB Capital Management LLC lowered its position in Tabula Rasa HealthCare, Inc. (NASDAQ:TRHC) by 50.9% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 24,270 shares of the company’s stock after selling 25,208 shares during the period. RMB Capital Management LLC’s holdings in Tabula Rasa HealthCare were worth $1,118,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Veriti Management LLC bought a new stake in Tabula Rasa HealthCare in the fourth quarter worth about $46,000. Vantage Consulting Group Inc bought a new stake in Tabula Rasa HealthCare in the fourth quarter worth about $50,000. Harel Insurance Investments & Financial Services Ltd. bought a new stake in Tabula Rasa HealthCare in the first quarter worth about $432,000. Everence Capital Management Inc. bought a new stake in Tabula Rasa HealthCare in the first quarter worth about $217,000. Finally, ProShare Advisors LLC bought a new stake in shares of Tabula Rasa HealthCare during the fourth quarter valued at approximately $219,000. 93.34% of the stock is owned by institutional investors and hedge funds.

Shares of NASDAQ:TRHC opened at $41.79 on Friday. The company has a market capitalization of $1.04 billion, a P/E ratio of -10.83 and a beta of 0.94. Tabula Rasa HealthCare, Inc. has a 52 week low of $30.12 and a 52 week high of $69.31. The company has a quick ratio of 1.31, a current ratio of 1.38 and a debt-to-equity ratio of 4.02. The business has a 50 day simple moving average of $43.51.

Tabula Rasa HealthCare (NASDAQ:TRHC) last issued its quarterly earnings data on Thursday, May 6th. The company reported ($0.09) EPS for the quarter, hitting analysts’ consensus estimates of ($0.09). The company had revenue of $76.70 million during the quarter, compared to the consensus estimate of $76.20 million. Tabula Rasa HealthCare had a negative net margin of 28.57% and a negative return on equity of 23.88%. Tabula Rasa HealthCare’s revenue for the quarter was up 5.4% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.01 earnings per share. As a group, equities analysts anticipate that Tabula Rasa HealthCare, Inc. will post -1.03 earnings per share for the current fiscal year.

In other Tabula Rasa HealthCare news, CAO Andrea Carolan Speers sold 695 shares of Tabula Rasa HealthCare stock in a transaction on Monday, May 24th. The shares were sold at an average price of $41.66, for a total value of $28,953.70. Following the transaction, the chief accounting officer now directly owns 62,851 shares of the company’s stock, valued at $2,618,372.66. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, COO Michael Greenhalgh sold 1,000 shares of Tabula Rasa HealthCare stock in a transaction on Wednesday, June 2nd. The stock was sold at an average price of $46.00, for a total transaction of $46,000.00. Following the completion of the transaction, the chief operating officer now directly owns 169,771 shares in the company, valued at $7,809,466. The disclosure for this sale can be found here. Insiders sold 41,695 shares of company stock valued at $1,729,834 in the last three months. 10.20% of the stock is currently owned by insiders.

Several analysts have recently weighed in on the stock. Piper Sandler lifted their price target on shares of Tabula Rasa HealthCare from $41.00 to $45.00 and gave the company a “neutral” rating in a research note on Friday, May 7th. Robert W. Baird assumed coverage on shares of Tabula Rasa HealthCare in a research note on Thursday, May 27th. They set an “outperform” rating and a $53.00 price target for the company. Cantor Fitzgerald reaffirmed a “neutral” rating and set a $40.00 price target on shares of Tabula Rasa HealthCare in a research note on Tuesday, March 2nd. SVB Leerink lifted their price target on shares of Tabula Rasa HealthCare from $43.00 to $49.00 and gave the company a “market perform” rating in a research note on Monday, May 10th. Finally, Zacks Investment Research raised shares of Tabula Rasa HealthCare from a “strong sell” rating to a “hold” rating in a research note on Tuesday, May 4th. Seven equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. Tabula Rasa HealthCare has an average rating of “Hold” and a consensus target price of $53.18.

Tabula Rasa HealthCare Profile

Tabula Rasa HealthCare, Inc operates as a healthcare technology company in the United States. The company operates through two segments, CareVention HealthCare and MedWise HealthCare. It offers EireneRx, a cloud-based medication decision-support and e-prescribing platform to access patient medication-related information; and MedWise software that provides medication decision support components for clients seeking to manage their medication risk and improve medication outcomes, and patient relationships by enhancing their existing programs or systems.

Read More: Why is momentum important to successful trading?

Want to see what other hedge funds are holding TRHC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Tabula Rasa HealthCare, Inc. (NASDAQ:TRHC).

Institutional Ownership by Quarter for Tabula Rasa HealthCare (NASDAQ:TRHC)

Receive News & Ratings for Tabula Rasa HealthCare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tabula Rasa HealthCare and related companies with MarketBeat.com's FREE daily email newsletter.